Real-World Data & Market Intelligence - software & AI news

Daily news on software, AI, and companies shaping real-world data & market intelligence.

Showing 58 results
Press release cover image

Oct 15, 2026

Colait Launches Neuroscience Data Collection Initiative, Advancing the Case for Clinical Opinion as a Core Layer of Real-World Evidence

Boston, October 15, 2026 — Colait today announced thelaunch of a structured clinical opinion data collection initiative inneuroscience, marking the company's first large-scale therapeutic area studyand a significant expansion of what will become the first nationally representativequalitative clinical opinion dataset across therapy areas.The announcement comes as industry leaders gather in Bostonthis week to examine the future of scientific innovation and the growingimperative to rebuild trust in
Stylized data stream representing market signals in biopharma

Oct 14, 2026

What's Next for Pharma Launches BioPharmaGPS, an AI-driven Portfolio & Market Access System for the BioPharmaceutical Industry

What's Next for Pharma has launched BioPharmaGPS, an innovative AI-driven system aimed at transforming decision-making within the biopharmaceutical sector.This new platform seeks to bridge gaps in the pharmaceutical industry by integrating diverse market signals with organizational expertise. BioPharmaGPS is designed to support biopharma leaders by providing tailored, actionable insights across five major markets: India, the EU, China, Japan, and the US. Through its three-layered approach, the s
Pharmaceutical products in a warehouse

Oct 14, 2026

Inside Cencora's Approach to AI-Driven Demand Sensing

Cencora is leveraging artificial intelligence to enhance its demand forecasting capabilities in the pharmaceutical sector, achieving a notable 10% improvement in accuracy.The company, represented by Matt Sample, highlights the limitations of traditional supply chain data, particularly the absence of real-time point-of-sale information that is common in consumer markets. To address this gap, Cencora has implemented an AI tool that analyzes historical forecasts alongside current ordering patterns.
A minimalist representation of an eye with a retina pattern, symbolizing oculomics.

Oct 9, 2026

Oku Digital Health launches from Topcon with AI retinal screening network, oculomics

Oku Digital Health has emerged as a significant player in the eyecare sector, leveraging AI technology to enhance patient care and streamline clinical workflows.Founded as a spin-off from Topcon Healthcare, Oku Digital Health aims to integrate routine eye examinations with broader health data, facilitating earlier detection of chronic diseases and improving care coordination. The company operates on a robust infrastructure that supports over 10,000 care locations globally, utilizing the concept
Press release cover image

Oct 8, 2026

New Study Shows Briya's AIRE AI Research Platform Expands Steatotic Liver Disease Identification by 360% Using Previously Overlooked Radiology Data

Briya AIRE's analysis of 28,795 abdominal ultrasound reports found 78% of steatotic liver patients were identified only through unstructured radiology reportsNEW YORK, Oct. 8, 2026 /PRNewswire/ -- Briya, the health AI company redefining healthcare research with AIRE, a trusted AI platform, today announced results from a real-world study demonstrating how AI and natural language processing (NLP) can uncover under-documented cases of metabolic dysfunction-associated steatotic liver disease (MASLD)
Press release cover image

Oct 8, 2026

EVERSANA and Pulse Infoframe Announce Strategic Partnership to Deliver Global Real-World Evidence and HEOR Solutions

Collaboration creates unmatched capabilities in biopharma industry for real world data generation and insights for market access strategyCHICAGO, Oct. 8, 2026 /PRNewswire/ -- EVERSANA, a leading provider of technology enabled, modern commercialization services to the biopharmaceutical industry, today announced a strategic partnership with Pulse Infoframe, a leader in real-world evidence (RWE) generation and intelligence. Through the partnership, EVERSANA will pair its end-to-end commercializatio
Press release cover image

Oct 5, 2026

Kymanox Launches KymaBridge, an Intelligence Platform Connecting Pharma and Biotech Innovators with Drug Delivery Device Technologies

New platform pairs Kymanox subject matter expert verification with supplier-confirmed data, helping sponsors identify the right drug delivery device technology faster, while giving device suppliers a direct, verified channel to showcase their products and capabilities.Raleigh-Durham, North Carolina; King of Prussia, Pennsylvania, USA; Bern, Switzerland, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Kymanox®, a leading global life sciences consulting and professional services firm supporting the development
Press release cover image

Oct 1, 2026

Flatiron Health's Breast Cancer Panoramic Dataset Surpasses One Million Patients, Enabling Real-World Research at Unprecedented Scale

Longitudinal, biomarker-rich real-world data supports precision medicine research across the full breast cancer continuumNEW YORK--(BUSINESS WIRE)--Flatiron Health, a leading healthtech company dedicated to improving cancer care and advancing research using real-world data, today announced that its Breast Cancer Panoramic dataset has surpassed one million patients — the largest rigorously curated breast cancer real-world dataset of its kind. This milestone arrives during Breast Cancer Awareness
Press release cover image

Sep 30, 2026

Lōkahi Therapeutics™ Announces Qare™, the First Real-Time Comparative Health Platform for GLP-1 Medications, with Public Availability Beginning October 14

Developed Through ai² Accelerator™, Qare™ Is Designed to Enable Users to Compare Their Experiences Against Cohorts of People Like Them, with Additional Drug Classes Expected to FollowRUTHERFORD, N.J. & LA JOLLA, Calif.--(BUSINESS WIRE)--Lōkahi Therapeutics™, a subsidiary of Glucotrack, Inc. (NASDAQ: GCTK), today announced Qare™, a comparative health platform designed to evaluate treatment outcomes by comparing experiences across patients using different medications within the same therapeuti
Press release cover image

Sep 30, 2026

People switching from weight-loss injections to Novo's Wegovy® pill lost 4.1% body weight on average after three months, according to real-world data presented at EASD2026

People with overweight or obesity who switched from injectable GLP-1 based therapies for weight management to oral semaglutide (Wegovy® pill) lost an average of 4.0 kg (8.8 lb) in three months (p<0.001)1At three months of switching to the pill, two in five participants (40.7%) achieved 5% or more weight loss, while the proportion of participants with BMI ≥30 kg/m² decreased by 21.6 percentage points (p<0.001)1Among participants with available data, most (82.4%) reported at least one treatm
Press release cover image

Sep 29, 2026

Truven Launches MarketScan Snapshot, an AI-powered Tool to Evaluate Fit-For-Purpose Real-World Data in Minutes

AI-powered capability gives teams a faster way to explore MarketScan's longitudinal closed-claims data, including 300M+ cumulative lives and 95M active lives, all with 99% claims completeness The story at a glance:By accelerating early data exploration, MarketScan Snapshot helps teams move from question to evidence generation with greater speed and confidence.MarketScan Snapshot is an AI-powered capability that enables users to explore MarketScan® Research Databases in plain language and identif
Press release cover image

Sep 29, 2026

Flatiron Health Expands Global Panoramic Datasets With AI-Powered Breast Cancer and NSCLC Real-World Data for the UK, Germany, and Japan

Second multinational launch builds on January prostate debut, extending cross-country oncology evidence ahead of ESMO 2026NEW YORK--(BUSINESS WIRE)--Flatiron Health, a leading healthtech company dedicated to improving cancer care and advancing research using real-world data, today announced the launch of Breast Cancer and Non-Small Cell Lung Cancer (NSCLC) Panoramic datasets in the UK, Germany, and Japan. This marks the next phase of Flatiron's global evidence expansion, following the company's